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 1 
Retention of Student Pharmacists' Knowledge and Skills Regarding Overdose Management 
with Naloxone 
 
Abstract 
 
Background:  Overdose education and naloxone training was recently implemented into the 
required curriculum of the College of Pharmacy at the University of Rhode Island.  The objective 
of this study was to compare the retention of knowledge between student pharmacists who 
received a didactic lecture only versus student pharmacists who received the same lecture plus 
a skills-based objective structured clinical examination (OSCE) with a standardized patient 
actor.   
 
Methods:  Students in their first-professional year (P1) of the Doctor of Pharmacy program 
(n=129) and students in their second-professional (P2) year (n=123) attended a required lecture 
on opioid overdose, including detailed naloxone training. P2 students were additionally required 
to participate in an OSCE assessment following the didactic lecture component.  An 
anonymous, voluntary survey was offered to all students approximately 6 months later.  A Chi-
Square or Fisher’s Exact Test was performed on the survey responses to assess any difference 
in the responses between the two groups. 
 
Results:  A total of 99 P1 students (76.7%) and 116 P2 students (94.3%) completed the survey.  
P1 students were found to be more knowledgeable regarding the duration of naloxone action 
and identification of risk factors for opioid overdose.  P2 students were found to be more 
knowledgeable regarding non-medical ways patients may obtain opioids and the correct order of 
emergency response during a suspected opioid overdose... 
 
Conclusions: P2 students did not demonstrate superior retention of information regarding 
naloxone and opioid use disorder on survey questions compared with P1 students.  There was 
a trend towards P2 students feeling more confident in their ability to counsel patients for 
overdose prevention and reporting disagreement with the statement that “overdose prevention 
for people who use drugs is a waste of time and money” compared with the P1 students, but 
these did not reach statistical significance.  Since the opioid crisis continues unabated, naloxone 
training using OSCE and didactic methods remain an on-going required part of the pharmacy 
curriculum.  
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Introduction  
  
The World Health Organization estimates that 69,000 people die each year due to drug 
overdose, with over 47,000 of these deaths in the United States alone.1 Of these deaths 33,000 
are related to opioid overdose. Prescription opioids, including morphine, oxycodone, 
hydrocodone, hydromorphone and fentanyl, as well as illicit substances such as heroin and 
contaminated non-pharmaceutical fentanyl are responsible for these opioid related deaths, 
which have tripled since the year 2000.1,2 
  
People at risk to experience an overdose are those who administer substances through non-
medical routes (i.e. injection or insufflation), utilize high doses of opioids, are co-prescribed 
benzodiazepines, are co-prescribed antidepressants or sedatives/hypnotics, utilize long-acting 
opioid formulations, use more potent opioid drugs (such as fentanyl), obtain opioid prescriptions 
from multiple providers and pharmacies, or have a history of mental illness, alcohol or 
substance abuse disorder.3–10  Opioid-related overdose risk is highest in those with decreased 
tolerance who relapse into use following a period of abstinence, such as time spent in 
detoxification programs or incarceration, particularly when quantities of drug used previously are 
reintroduced.11,12 Patients receiving 100 or more morphine milligram equivalents (MME) per day, 
compared to patients with less than 100 MME, have been shown to have an 8.9-fold increase in 
risk of opioid overdose.10 Many overdoses occur in the presence of one or more bystanders and 
with proper training and tools, especially the opioid-reversal agent naloxone, these individuals 
could potentially save lives by stopping an overdose from progressing.13  
  
Naloxone is a centrally- and peripherally acting mu-, delta-, and kappa- opioid receptor 
antagonist which can be used to reverse opioid activity in overdose situations. Naloxone can be 
administered intranasally, intramuscularly, intravenously, intralingually, and subcutaneously to 
reverse respiratory depression and analgesia. Once administered, naloxone has an onset of 5 
to 10 minutes and a duration of 30 to 90 minutes. The time to administration of a second dose in 
response to no effect seen with the first dose varies among routes of administration and relative 
time of onsets for each route. Volunteers given up to 100 times the therapeutic dose of 
naloxone suffered no adverse effects, which demonstrates the safety of the agent and enables 
the public to administer naloxone even in the absence of extensive training.14,15 
  
Given the proper resources, such as integrated access to the prescription drug monitoring 
program with the dispensing software used to process and prepare prescriptions in community 
pharmacies, pharmacists have the opportunity to make a significant impact on community-level 
prescription substance use disorder prevention and treatment efforts.16 Pharmacists have daily 
contact with patients who are either at risk for opioid overdose themselves or know someone at 
risk.17 Through required clinical patient care rotations (Introductory Pharmacy Practice 
Experiences and Advanced Pharmacy Practice Experiences) and internships student 
pharmacists will encounter persons at risk for opioid overdose in community pharmacy practice 
and other settings.  Any interaction between student pharmacists and patients is a possible 
opportunity to identify opioid overdose risk factors and make interventions.  Therefore, student 
pharmacists should be trained to identify these patients at risk and be able to provide naloxone 
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education and training.18 
  
This study seeks to assess differences in the retention of knowledge (objective data) and 
impressions of overdose prevention efforts (subjective data) between student pharmacists who 
received the content delivered by a 50-minute lecture only and those who received the same 
lecture and completed an objective structured clinical examination (OSCE) of interactive 
counseling with standardized patient actors. Overdose education and naloxone training was 
recently implemented into the required curriculum of the College of Pharmacy at the University 
of Rhode Island in an effort to better prepare student pharmacists to identify intervention 
opportunities with at-risk patients. To better understand the most effective way to perform 
naloxone training and opioid overdose education this comparative study between two classes of 
Doctor of Pharmacy students was performed. We hypothesized that students who receive a 
lecture plus OSCE would score higher on the objective portion of a six month follow-up survey 
about overdose and naloxone education versus students who receive a lecture only.19   
 
An OSCE format was utilized in this study due to reinforcement and retention rates 
demonstrated in the literature. OSCEs have been noted to increase retention of knowledge 
rather than just didactic lecture across multiple topics. One study of intern-level medical 
students found that 75% of interns were able to achieve a passing score of 60% up to 18 
months after an OSCE, and the remaining 25% of interns who did not pass the original OSCE 
quickly re-learned skills.20 Another study with Doctor of Pharmacy students found that students 
working in a simulated environment displayed increased enthusiasm toward the OSCE topic 
and retention of developed clinical skills, as opposed to conventional written patient cases.21 
  
Methods 
  
First (P1) and second (P2) professional year student pharmacists at the University of Rhode 
Island are required to take the skills-based Integrated Pharmacy Laboratories I and III (PHC 316 
and PHC 416) in the Spring semester. All 129 students in the first-professional year and 123 
students in the second-professional year were eligible for study participation by attending the 
same lecture on overdose response including detailed naloxone training. Second-professional 
year students were additionally required to participate in an OSCE with a standardized patient 
actor following the didactic lecture component. Students were surveyed approximately 6 months 
after they participated in the lecture or lecture plus OSCE in order to assess retention of 
material related to key points of opioid use disorder, overdose identification, and naloxone 
administration.  The study methodology and survey instrument was reviewed and deemed to be 
exempt by the University of Rhode Island Institutional Review Board. 
  
The lecture portion of the training consisted of information regarding naloxone, overdose and 
opioid use disorder.22–24 The OSCE required students to further prepare themselves for a 
simulated patient interaction where they would be required to teach an at-risk patient how to 
identify an overdose, check for response, call 911, give rescue breaths, properly assemble and 
administer intranasal naloxone, and what to expect after naloxone administration.25 Preparation 
was highly recommended for the mock-patient scenario, which was a team-based graded 
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assignment. The overall goal of the OSCE was to have the students assess the patient’s need 
for naloxone, teach the patient the steps of responding to an opioid overdose including 
administration of naloxone, and evaluate the patient’s ability to teach others close to him how to 
respond in the event of an opioid overdose. Students in teams of 5 or 6, were responsible for 
screening the patient, a local paid actor, for opioid use disorder and risk of opioid overdose 
through a complete history, physical exam, and review of systems.26 One or two members of the 
group were then responsible for counseling the patient about naloxone including its indication, 
duration of action, side effects, and what to expect once administered. One other team member 
was responsible for demonstrating to the patient how to use the atomizer/intranasal naloxone kit 
and then asking the patient to perform naloxone administration using the teach-back method.  
The multi-step intranasal kit was selected over the intramuscular versions since the auto-injector 
is dispensed with a ‘talking” trainer and the multi-step intranasal kit was the only intranasal 
formulation widely marketed and used in New England at the time of the study.27–29 The goal of 
the teach-back method was to ensure patient confidence with the information provided and 
assess his ability to teach proper naloxone administration to his 10-year-old daughter in the 
event of an overdose situation. 
  
The follow-up survey was given as a 21-item multiple choice questionnaire offered via 
SurveyMonkey® to all students who participated in the naloxone lecture or lecture plus OSCE 
approximately 6 months after the course content was completed.30,31 Informed consent 
information was included at the beginning of the online survey for all participants and 
participation was indicative of consent. The survey was offered in class to all 252 students, of 
which 129 students received lecture only and 123 students received both the lecture and OSCE. 
The survey took approximately 5-10 minutes to complete and students were given the 
opportunity to skip any questions at any time.  The survey consisted of 7 fact-based (objective) 
and 14 opinion-based (subjective) questions regarding opioid overdose, opioid use disorder, 
and use of naloxone.  Survey completion was completely voluntary and students could opt out 
of any individual question they did not wish to answer, with no incentives nor impact on course 
grades.  The time in class could be used by those students opting not to participate in the 
survey for other independent activities, such as reading or reviewing class notes.  Responses to 
these items were collected through a secure surveying website and kept on a password-
encrypted computer. All surveys were anonymous, and de-identified data was compiled which 
contained no unique identifiers. No link to student names or identifying information were asked 
in the survey, however, the timing of the survey administration indicated the class (P1 or P2).   
 
Survey questions were developed by the researchers and were influenced by materials found 
on the Prescribe to Prevent website and continuing education programs.32 A Chi-Square or 
Fisher’s Exact Test was performed on each of the questions to assess any difference in the 
responses between the two groups.  A significance level of α=0.05 was set a priori.  This 
analysis was chosen due to the independent nature of comparison between the two groups of 
pharmacy students.   
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Results 
  
Of the 252 students that received the didactic lecture covering naloxone administration and 
opioid overdose, a total of 215 (85.3%) students participated in the survey.  A total of 99 
students of the P1 students (76.7%) and 116 students of the P2 students (94.3%) completed the 
survey. As a whole, the P1 class answered 96.97% to 100% of questions and P2s answered 
99.14% to 100% of the questions.  Table 1 shows the results of each individual objective 
question. The hypothesis of the study was that P2 students who experienced both the lecture 
and the OSCE activity would score higher on survey questions versus the P1 students who 
experience the same lecture alone. Four objective questions were found to have a statistically 
significant difference in correct responses between the P1 and P2 students (p<0.05).  P2 
students were significantly more knowledgeable on questions relating to ways prescriptions 
opioids are obtained for non-medical use and the correct order of steps in an overdose 
response situation.  P1 students were significantly more knowledgeable on questions related to 
the duration of action of naloxone and greatest risk factors for opioid overdose.   
  
Student responses to subjective or opinion-based questions are shown in Table 2.  Responses 
were gathered by asking students to rank their impression of statements into one of three 
categories:  Agree/True, Neutral, or Disagree/False.  P2 students reported higher rates of 
working in a community pharmacy practice setting at the time of survey administration than did 
the P1 students (p<0.05).  While there was a trend towards P2 students reporting increased 
confidence versus P1 students when asked to counsel patients on overdose prevention and 
disagreeing with the statement “overdose prevention for people who use drugs is a waste of 
time and money”, these did not reach statistical significance. 
 
Discussion  
  
Patients using opioids are experiencing mortality and morbidity from opioid overdoses at 
epidemic rates in the United States.33  As healthcare professionals who are in direct contact with 
patients who may be at risk for overdose, pharmacists have a duty to combat this epidemic by 
identifying at-risk patients and counseling them about response to an overdose and naloxone 
administration.14 This study was conducted to compare retention of overdose and naloxone 
knowledge between first year Doctor of Pharmacy students who received a didactic lecture 
alone versus second year students who participated in both a didactic lecture and a hands-on 
OSCE experience.  Our study found significant differences in the responses to individual 
questions regarding naloxone and opioid overdose between the two groups, however the P2 
students did not perform significantly better overall on the objective questions as hypothesized.  
 
Interdisciplinary teaching programs that include naloxone training should be designed to meet 
competencies similar to those established in Massachusetts for medical students, namely 
“recognize the risk factors for, and signs of, opioid overdose and demonstrate the correct use of 
naloxone rescue.”34,35 The most current substance use disorder curricular competencies for 
pharmacists do not include naloxone education as part of comprehensive harm reduction 
training and require updating.36,37 This is especially important since pharmacy students possess 
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higher than average prevalence of risky substance use behaviors38 and are an essential 
component of overdose prevention and response.18,39 Surveys of practicing pharmacists have 
shown that despite successful programs on overdose education,40 pharmacists continue to lack 
confidence and willingness to prescribe and dispense naloxone.41,42 
 
One way to easily integrate training with an active learning component is to pair naloxone 
training with basic life support training a requirement of nearly all health professional 
schools.14,43 One study showed that while health professional training can be successful, a 
“cascade” approach to train other clinicians and then end-users of naloxone faces more 
barriers, further justifying required education of clinicians-in-training directly.44 A study of 
another public health training currently offered in pharmacy curricula nationwide, immunization 
training, did not demonstrate significant differences in confidence and knowledge based on 
student year in the program, indicating that training is feasible even early in the curriculum.45 
The authors of this study also concluded that active learning should be integrated into 
immunization training, which informed our decision to include the active learning component of 
the OSCE in naloxone training.    
 
Limitations 
 
There are several limitations to this study, including potential differences in patient care 
experience between P1 and P2 students and the timing of survey administration.  Some of the 
differences may have been due to P2 students simply having more experience and knowledge 
than P1 student.  P2 students reported higher rates of employment in community pharmacy and 
would have more experience through Introductory Pharmacy Practice Experiences (IPPE), 
which are part of the required Doctor of Pharmacy curriculum.  It is unknown however if P2 
students would have had more exposure to opioid use disorders or overdose response topics in 
these settings however as employment and IPPE sites vary widely in the amount of patient 
contact provided and focus of the experience.  Another limitation is that the survey for P2 
students was sent via link in an email over summer break when students were not actively 
engaged in pharmacy courses. This contrasted with the P1 students who were given the 
opportunity to complete the survey while in class during the semester.  While the study findings 
did not support our hypothesis that P2 students would have superior retention of knowledge 
related to opioid overdose and naloxone, we believe that the trend towards subjective response 
differences between the P1 and P2 students are important and illustrate both increased 
confidence with patient counseling and a reduced stigma for those who received an OSCE 
activity versus a lecture alone.  Future studies should continue to enroll not only pharmacy 
students in studies of knowledge retention, confidence, and other subjective measure, but 
should include all health professional students.  
 
Conclusions 
 
We found that retention of the order of steps for naloxone administration when counseling 
patients on response to an overdose was increased among surveyed P2 students who received 
training from a didactic lecture plus an OSCE as compared to P1 student pharmacists who 
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received a lecture only, however overall fact-based knowledge related to naloxone and opioids 
was similar. We have retained both teaching components in our curriculum based on the 
strength of OSCE as a tool for teaching addiction,46,47 the unremitting opioid epidemic in our 
state and region, and positive trends among surveyed P2 students related to an increased 
perception that overdose prevention with naloxone is not a waste of time or money.  
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